Pathios Therapeutics is an early-stage drug discovery company headquartered in Oxford, UK.

The company is founded upon a deep understanding of the biology of the acid-sensing GPCR, GPR65, in tumour-associated macrophages (TAMs) and Th17 cells. Pathios are engaged in a fully-enabled drug discovery program to identify novel small-molecule modulators of GPR65 with expected utility in cancer and certain autoimmune conditions. Pathios employs a cutting edge scientific approach to mapping the signalling of GPR65 on immune cells based on human genetic insights, transcriptomics and state-of-the-art cellular immunology, aiming to deliver first in class medicines that target this receptor and have the potential for therapeutic benefit in a range of diseases. The company combines a team of experienced scientific leaders with a number of strategic external partnerships, including Melbourne’s St Vincent’s Institute (SVI) of Medical Research and The Queensland University of Technology (QUT) in Brisbane, which allows it to efficiently carry out a range of drug discovery and scientific activities, capitalising on the very latest advances in GPCR drug discovery.